Neogen (NASDAQ:NEOG) Stock

Neogen

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.

Earnings

Earnings Beats

Large Cap

Macro Economic Events

Mid Cap

News

Economics

Markets

Analyst Ratings

Trading Ideas

ISRG

NEOG

TMDX

Neogen&#39;s (NASDAQ: NEOG) vast international trade is impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell).

Neogen&#39;s international business continues to be affected by currency movements.

Neogen Suffers From Competitive Pressure, Macroeconomic Woes

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MEDP

Neogen Corporation (NASDAQ: NEOG) effectively progresses with its strategic growth pillars, placing the company well for future success. The Animal Safety segment thrives from the successful consumables product line and also boasts a promising future in genomic services.

Here&#39;s Why Staying Invested in Neogen Could be Beneficial

Screenshot 2024-06-28 at 6.21.18 PM

Long Ideas

Short Ideas

Technicals

ETFs

Inflation Slows Small Cap Rally, But SMCP ETF Offers Strategic Entry Point

Neogen Corp

NEOGAMES SA SHS USD

NeoGenomics Inc

<p>The claim was withdrawn following a mutual agreement, with no admission of wrongdoing by Neogen.</p>
<p>In the coming weeks,&nbsp;Lansing warehouse shipping clerks and material handling employees will have the opportunity to vote in an election to determine whether they wish to unionize.</p>


Neogen Says National Labor Relations Board Has Withdrawn Its Unfair Labor Practices Claim Against Company

<p>Piper Sandler  analyst David Westenberg   reiterates Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and lowers the price target from $16.5 to $13.</p>


Price Target

Reiteration

Piper Sandler Reiterates Neutral on Neogen, Lowers Price Target to $13

Neogen Corporation Launched It's Igenity BCHF To Improve Overall Bovine Heart Health Standards

General

NeoGenomics shares are trading higher following strong FY25 guidance.

Neogen Files For Non-Timely 10-Q With U.S. SEC; Expects To Record An Impairment Charge Of $461.4M In Q2; Expects Form 10-Q Will Report Net Loss Of $456.3M For Qtr Ended Nov 30, 2024

WIIM

Neogen shares are trading lower after the company issued FY25 revenue guidance below estimates.

Neogen Corporation Sees Fy25 Revenue Of $905M-$925M Vs. $934.88M Estimate (Prior View: $925M-$955M)

<p>Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $0.10 by 10 percent.  The company reported quarterly sales of $231.258 million which beat the analyst consensus estimate of $227.159 million by 1.80 percent.  This is a 0.71 percent increase over sales of $229.629 million the same period last year.</p>


Neogen Q2 2025 Adj. EPS $0.11 Beats $0.10 Estimate, Sales $231.258M Beat $227.159M Estimate

<h3>Companies Reporting Before The Bell</h3>
<p>• Constellation Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>) is likely to report quarterly earnings at $3.32 per share on revenue of $2.54 billion. </p>
<p>• E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $161.00 million. </p>
<p>• Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $226.65 million. </p>
<p>• Walgreens Boots Alliance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>) is expected to report quarterly earnings at $0.46 per share on revenue of $37.20 billion. </p>
<p>• Tilray Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLRY#NASDAQ">TLRY</a>) is projected to report earnings for its second quarter. </p>
<p>• TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $3.07 per share on revenue of $15.30 billion. </p>
<p>• Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) is projected to report quarterly earnings at $1.74 per share on revenue of $14.64 billion. </p>
<h3>Companies Reporting After The Bell</h3>
<p>• WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) is projected to report quarterly earnings at $1.31 per share on revenue of $147.44 million. </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ETWO

TLRY

WDFC

Earnings Scheduled For January 10, 2025

<p>Guggenheim  analyst Subbu Nambi   initiates coverage on Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Buy rating and announces Price Target of $15.</p>


Initiation

Guggenheim Initiates Coverage On Neogen with Buy Rating, Announces Price Target of $15

Neogen shares are trading lower after the company reported worse-than-expected Q1 adjusted EPS results. Also, the company announced its COO will retire in early 2025.

<p>Neogen&rsquo;s operations organization will transition to report to David H. Naemura, Chief Financial Officer. Mr. Jones will work closely with Mr. Naemura on this transition. Mr. Jones also will continue to lead the commercial organization until the Chief Commercial Officer role is filled and will oversee the transition of this function to his successor.</p>


Management

Neogen COO Douglas E. Jones Intends To Retire In Early 2025 - Filing

<p>Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) affirms FY2025 sales outlook from $925.00 million-955.00 million to $925.00 million-955.00 million.</p>


Guidance

Neogen Affirms FY2025 Sales Guidance to $925.00M-955.00M (Est. 934.885M)

<p>Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.09 by 22.22 percent.  The company reported quarterly sales of $217.000 million which beat the analyst consensus estimate of $215.056 million by 0.90 percent.  This is a 5.23 percent decrease over sales of $228.987 million the same period last year.</p>


Earnings Misses

Neogen Q1 2025 Adj. EPS $0.07 Misses $0.09 Estimate, Sales $217.000M Beat $215.056M Estimate

<p><strong>Neogen</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) is set to give its latest quarterly earnings report on Thursday, 2024-10-10. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Neogen will report an <strong>earnings per share</strong> (EPS) of $0.08. </p>
<p>Investors in Neogen are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous earnings release, the company missed EPS by $0.01, leading to a 3.13% drop in the share price the following trading session.</p>
<p>Here's a look at Neogen's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.11</td>
<td>0.14</td>
<td>0.14</td>
<td>0.12</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>0.12</td>
<td>0.11</td>
<td>0.11</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-3.0%</td>
<td>-4.0%</td>
<td>3.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728482425_0.png" alt="eps graph" /></p>
<h3>Tracking Neogen's Stock Performance</h3>
<p>Shares of Neogen were trading at $14.69 as of October 08. Over the last 52-week period, shares are down 2.27%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Analyst Opinions on Neogen</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Neogen.</p>
<p>With 1 analyst ratings, Neogen has a consensus rating of Neutral. The average one-year price target is $17.5, indicating a potential 19.13% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Haemonetics, UFP Techs and ICU Medical, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Haemonetics is maintaining an Outperform status according to analysts, with an average 1-year price target of $105.57, indicating a potential 618.65% upside.</li>
<li>Analysts currently favor an Buy trajectory for UFP Techs, with an average 1-year price target of $392.0, suggesting a potential 2568.48% upside.</li>
<li>The consensus among analysts is an Outperform trajectory for ICU Medical, with an average 1-year price target of $165.0, indicating a potential 1023.21% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>Within the peer analysis summary, vital metrics for Haemonetics, UFP Techs and ICU Medical are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neogen</td>
<td>Neutral</td>
<td>-2.07%</td>
<td>$113.48M</td>
<td>-0.17%</td>
</tr>
<tr>
<td>Haemonetics</td>
<td>Outperform</td>
<td>7.98%</td>
<td>$174.92M</td>
<td>4.11%</td>
</tr>
<tr>
<td>UFP Techs</td>
<td>Buy</td>
<td>10.14%</td>
<td>$33.03M</td>
<td>4.48%</td>
</tr>
<tr>
<td>ICU Medical</td>
<td>Outperform</td>
<td>8.58%</td>
<td>$207.43M</td>
<td>-1.04%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Neogen ranks at the bottom for Revenue Growth among its peers. It is also at the bottom for Gross Profit. For Return on Equity, Neogen is at the bottom.</p>
<h3>Get to Know Neogen Better</h3>
<p>Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.</p>
<h3>Financial Insights: Neogen</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Neogen faced challenges, resulting in a decline of approximately <strong>-2.07%</strong> in revenue growth as of 31 May, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Neogen's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-2.29%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.17%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Neogen's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.12%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.28</strong>.</p>
<p><a href="https://www.benzinga.com/quote/NEOG/earnings"><strong>To track all earnings releases for Neogen visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


A Glimpse of Neogen's Earnings Potential

<p><strong>Neogen</strong>&#39;s (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/neog#NASDAQ">NEOG</a>) vast international trade is impacted by global macroeconomic issues. Also, a tough competitive landscape weighs on the stock. NEOG stock carries a Zacks Rank #4 (Sell).</p>
<p>Neogen&#39;s international business continues to be affected by currency movements.</p>
<p>The current macroeconomic environment has adversely impacted Neogen&#39;s financial operations. Governments and insurance companies continue to look for ways to contain the rising cost of healthcare. This might put pressure on players in the healthcare industry, with Neogen being no exception.&nbsp; Although the company is gradually coming out of the impact of the two-and-a-half-year-long pandemic, deteriorating international trade, with global inflationary pressure leading to a tough situation related to raw material and labor cost as well as freight charges, and a higher interest rate have put the medical device space in a tight spot.</p>
<p>With sustained macroeconomic pressure, the company may struggle to keep its cost of revenues and operating expenses in check. In fiscal 2024, sales and marketing expenses rose 29.5% year over year. Our model forecasts a 1.5% rise in the metric for fiscal 2025.</p>
<p>Further, Neogen faces intense competition from companies ranging from small businesses to divisions of large multinational companies. Some of these organizations have substantially greater financial resources than the company. Historically, Neogen has faced intense competition resulting from the development of new technologies by the company&#39;s competitors, which could affect the marketability and profitability of Neogen&#39;s products.</p>
<h2>Factors That May Offset the Risks for NEOG Stock</h2>
<p>Neogen is progressing well in terms of picking the right growth markets and gaining a bigger share of those markets. In the fiscal fourth quarter, the Indicator Testing, Culture Media &amp; Other product categories benefited from double-digit growth in the Petrifilm product line as well as solid growth in culture media and food quality nutritional analysis. Additionally, the Vet Instruments and Disposables product line witnessed solid core growth. In the Animal care and other product category, core growth was led by higher sales of vitamin injectables and Biologics products.</p>
<div class="chart_embed">
<h2>Neogen Corporation Price</h2>
<p><img alt="Neogen Corporation Price" src="https://staticx-tuner.zacks.com/images/charts/a6/1724841357.png" style="height:251px; width:538px" title="" /></p>
<p>Neogen Corporation price | Neogen Corporation Quote</p>
<p>Neogen also continues to carry out its strong R&amp;D activities. During the fiscal fourth quarter, Neogen&#39;s R&amp;D expenses totaled $5.1 million, up sequentially 4.1%.</p>
</div>
<p>The company is expanding well in other geographies. The company is seeing double-digit sales growth in Latin America, with strong performance across most key product categories.&nbsp; The business in Europe and Asia Pacific grew in low single digits and mid-single digits, respectively, with strength in Culture media, Petrifilm, General Sanitation and Sample Handling.</p>
<h2>Key Picks</h2>
<p>Some better-ranked stocks in the broader medical space are <strong>Intuitive Surgical</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/isrg#NASDAQ">ISRG</a>), <strong>TransMedics Group </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) and <strong>Boston Scientific </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bsx#NYSE">BSX</a>). While Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, Boston Scientific currently carries a Zacks Rank of 2 (Buy).</p>
<p>Intuitive Surgical&#39;s shares have surged 55.4% in the past year. Estimates for the company&#39;s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.</p>
<p>ISRG&#39;s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.</p>
<p>Estimates for TransMedics&#39; 2024 earnings per share have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 174.1% in the past year compared with the industry&#39;s 9.2% growth.</p>
<p>TMDX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.</p>
<p>Estimates for Boston Scientific&#39;s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 46% compared with the industry&#39;s 9.2% growth.</p>
<p>In the last reported quarter, BSX delivered an earnings surprise of 6.90%. BSX&#39;s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.</p>
<p><a href="https://www.zacks.com/stock/news/2328483/neogen-suffers-from-competitive-pressure-macroeconomic-woes?cid=CS-BENZ-FT-analyst_blog|zer_report_update-2328483">To read this article on Zacks.com click here.</a></p>


<p>Piper Sandler  analyst David Westenberg   maintains Neogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEOG#NASDAQ">NEOG</a>) with a Neutral and raises the price target from $17 to $17.5.</p>


Piper Sandler Maintains Neutral on Neogen, Raises Price Target to $17.5

Neogen shares are trading higher after the company reported better-than-expected Q4 revenue results.

Health Care

Neogen Expects FY2025 Adjusted EBITDA Of $215M-$235M, While Capital Expenditures Are Expected To Be Approximately $85M, Including Approximately $55M Related Specifically To The Integration Of The Former 3M Food Safety Division

Neogen Initiates Its Full-year Outlook For Fiscal Year 2025, With Revenue Guidance Of $925M-$955M Versus Consensus Of $938.743M

Press Releases

Neogen® To Participate in 2024 UBS Global Healthcare Conference

Neogen® to Participate in the 36th Annual Piper Sandler Healthcare Conference

Neogen® Launches Petrifilm® Bacillus cereus Count Plate to Enhance Food Safety Testing Efficiency

Neogen® Announces Second-Quarter Earnings Release Date

Neogen® Announces Change to Second-Quarter Earnings Release Date

Neogen® To Participate in Upcoming Investor Conferences

Neogen Announces Preliminary¹ Second-Quarter 2025 Results

Neogen® Launches New MDA2 Quantitative Salmonella Molecular Detection Assay

Neogen® Introduces Igenity® BCHF to Help Industry Mitigate Bovine Congestive Heart Failure Risk

Comments

Neogen

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga